Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The dal-HEART Program:<br />
Dalcetrapib HDL Evaluation, Atherosclerosis,<br />
and Reverse Cholesterol Transport<br />
dal-VESSEL<br />
450 patients with<br />
CHD or CHD risk<br />
equivalent<br />
To evaluate the<br />
effect of<br />
dalcetrapib on<br />
endothelial<br />
function and BP,<br />
measured by<br />
FMD and ABPM<br />
dal-PLAQuE<br />
130 patients with<br />
CHD<br />
To evaluate the<br />
effect<br />
of dalcetrapib<br />
on<br />
inflammation,<br />
plaque<br />
size, and burden,<br />
measured by<br />
PET/CT and MRI<br />
scans<br />
dal-PLAQUE 2<br />
900 patients<br />
with CAD<br />
To evaluate the<br />
effect of<br />
dalcetrapib on<br />
CVD<br />
progression,<br />
assessed by<br />
IVUS<br />
and carotid Bmode<br />
ultrasound<br />
dal- ACUTE<br />
300 patients<br />
with ACS<br />
To evaluate<br />
the safety and<br />
efficacy of<br />
dalcetrapib in<br />
patients<br />
hospitalized for<br />
ACS. Treatment<br />
initiated within<br />
1 week a nd<br />
last for 20<br />
weeks<br />
ACS=acute coronary syndrome; FMD=flow-mediated dilation; ABPM=ambulatory blood pressure monitoring;<br />
CAD=coronary artery disease; IVUS=intravascular ultrasound; PET=positron emission tomography;<br />
CT=computed tomography; MRI=magnetic resonance<br />
Schwartz GG, et al. Amer. Heart J. 2009;158:896-901<br />
55